Seek Labs Launches Open Impact Program for Neglected Diseases
SALT LAKE CITY, Utah — September 22, 2026 SALT LAKE CITY, Utah — September 22, 2026 — Seek Labs...
Infectious Diseases
Advertisement
Quest Diagnostics Finds High Tick-Borne Disease Co-Exposure
Secaucus, New Jersey, U.S., September 21, 2026 Quest Diagnostics and researchers from the University of North Carolina at Chapel...
Armata Pharmaceuticals Highlights AP-SA02 Data at ISSSI 2026
Marina del Rey, California, U.S., September 21, 2026 Armata Pharmaceuticals announced that new data evaluating AP-SA02, its investigational bacteriophage...
Lakewood-Amedex Advances Nu-3 Phase 2a Clinical Trial
Sarasota, Florida, September 18, 2026 Lakewood-Amedex Biotherapeutics Inc. has announced that it has received central and all clinical-site Institutional...
Bright Path Labs Receives FDA AMT Designation for Medicines
Mesa, Arizona, U.S., September 14, 2026 Bright Path Labs, a U.S.-based pharmaceutical manufacturer, announced that the U.S. Food and...
Advertisements
Armata’s AP-SA02 Receives FDA Breakthrough Designation
Los Angeles, California, U.S., September 14, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has...
AdJane Unveils mRNA Mucosal Booster Vaccine Strategy
Delft, The Netherlands, September 10, 2026 AdJane Biosciences has announced the publication of a new white paper, “Boosting mRNA:...
XYRA Doses First European Patient in Budiodarone Trial
BASEL, Switzerland, Aug. 31, 2026 XYRA LLC announced that the first patient in Europe has been dosed in the...
Kyowa Kirin Reaches U.S. Agreement to Lower Medicine Costs
TOKYO, Japan and PRINCETON, New Jersey, Aug. 31/Sept. 1, 2026 Kyowa Kirin Co., Ltd. announced a voluntary agreement with...
GSK Advances mRNA Flu Vaccine to Phase III After Data
LONDON, UK, Sept. 1, 2026 GSK announced that it will advance its investigational mRNA seasonal influenza vaccine candidate into...
Advertisement
